Ligand Pharmaceuticals
LGND
208 hedge funds and large institutions have $1.67B invested in Ligand Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 71 increasing their positions, 80 reducing their positions, and 35 closing their positions.
109% more call options, than puts
Call options by funds: $7.21M | Put options by funds: $3.44M
6% less funds holding
Funds holding: 221 → 208 (-13)
7.48% less ownership
Funds ownership: 156.24% → 148.76% (-7.5%)
11% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 80
33% less capital invested
Capital invested by funds: $2.51B → $1.67B (-$840M)
37% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 35
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.8M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$15.6M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.57M |
| 4 |
Morgan Stanley
New York
|
+$7.52M |
| 5 |
CC
Chicago Capital
Chicago,
Illinois
|
+$6.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$56.6M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$30.1M |
| 3 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$25.1M |
| 4 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
-$13.3M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$6.99M |
LGND Hedge Fund Activity: Q1 2022 in Review
208 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2022, worth a combined $1.67B — down 33% from $2.51B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of LGND and 22 opened new positions — a net loss of 13 holders — while 80 trimmed existing stakes and 71 added.
The largest buyer was State Street, adding an estimated $23.8M. The largest seller was William Blair Investment Management, cutting an estimated $56.6M.
- 208 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2022, down from 221 in Q4 2021.
- Funds reported $1.67B of Ligand Pharmaceuticals stock for Q1 2022, down 33% quarter-over-quarter.
- 22 funds opened new Ligand Pharmaceuticals positions in Q1 2022 and 35 closed out, a net change of -13 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2022 was State Street, an estimated $23.8M added.
- The largest Ligand Pharmaceuticals seller in Q1 2022 was William Blair Investment Management, an estimated $56.6M sold.
Based on aggregated 13F filings for Q1 2022.